Annual report [Section 13 and 15(d), not S-K Item 405]

Business Combination (Tables)

v3.26.1
Business Combination (Tables)
12 Months Ended
Dec. 31, 2025
Business Combination  
Schedule of fair value of consideration

​

​

​

​

​

​

  ​ ​ ​

​

  ​

Fair value of common stock issued

​

$

893,093

Fair value of preferred stock issued

​

​

70,372,634

Total Consideration Paid

​

$

71,265,727

Schedule of allocation of purchase price to fair values of assets and liabilities acquired

​

​

​

​

Assets acquired:

​

​

​

Cash

​

$

3,762,000

Prepaid expenses and other current assets

​

​

380,000

Property and equipment

​

​

19,000

In-process research and development assets

​

​

69,500,000

Goodwill

​

​

12,493,727

Right-of-use asset - operating leases

​

​

230,000

Total assets acquired

​

$

86,384,727

Liabilities assumed:

​

 

  ​

Accounts payable

​

$

904,000

Accrued expenses and other current liabilities

​

 

2,017,000

Deferred tax liability

​

​

11,968,000

Operating lease liabilities

​

​

230,000

Total liabilities assumed

​

$

15,119,000

​

​

​

​

Net assets acquired

​

$

71,265,727

Schedule of intangible assets acquired

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

 

​

​

​

Carrying Value

​

​

​

 

​

​

​

Carrying Value

​

​

​

​

​

​

​

 

​

​

​

as of

​

​

​

 

​

​

​

as of

​

​

Combination Date

​

​

​

 

​

​

​

December 31, 

​

​

​

 

​

​

​

December 31, 

​

  ​ ​ ​

Fair Value

  ​ ​ ​

Impairment

  ​ ​ ​

Translation Adj

  ​ ​ ​

2024

  ​ ​ ​

Impairment

  ​ ​ ​

Translation Adj

  ​ ​ ​

2025

Halneuron® for Cancer Related Pain

​

$

59,900,000

​

$

—

​

$

(3,266,035)

​

$

56,633,965

​

$

—

​

$

2,822,194

​

$

59,456,159

Halneuron® for Chemotherapy Induced Neuropathic Pain

​

 

9,600,000

​

​

—

​

 

(523,438)

​

 

9,076,562

​

​

—

​

 

452,305

​

 

9,528,867

Total in-process research and development (IPR&D)

​

$

69,500,000

​

$

—

​

$

(3,789,473)

​

$

65,710,527

​

$

—

​

$

3,274,499

​

$

68,985,026

​

​

 

​

​

​

​

​

​

​

​

 

​

​

​

​

​

​

​

​

 

​

Goodwill

​

$

12,493,727

​

$

—

​

$

(681,251)

​

$

11,812,476

​

$

—

​

$

588,642

​

$

12,401,118

Schedule of unaudited pro forma information

​

​

​

​

​

​

​

 

December 31, 

​

(In thousands)

  ​ ​ ​

2024

  ​ ​ ​

Net revenues

​

$

—

​

Net loss before taxes

​

$

(19,649)

​